SMARCA2 and prostate carcinoma: It was identified during studies on mammalian cell resistance to certain antibiotics in vitro.734 ADAADi binds to specific motifs in the enzyme complex, inducing conformational changes that inhibit SWI2/SNF2’s catalytic activities.734 Currently, ADAADi shows promising therapeutic effects in prostate cancer in preclinical studies, laying the groundwork for further development of SWI/SNF-targeted epigenetic drugs.735